This requires Flash to play. Click here to download.
MERCK

The information on this site is intended for healthcare professionals in the United States and is not intended for the general public.

I AM A HEALTHCARE PROFESSIONAL I AM NOT A HEALTHCARE PROFESSIONAL
Zolinza® [vorinostat] capsules Reactivate Expression
Home About ZOLINZA Efficacy Safety Profile Dosage Reimbursement Physician Resources Patient Education CTCL Overview Prescribing Information Patient Product Information
Patient Product Information

ePrints

Olsen EA, Kim YH, Kuzel TM, et al. Phase IIb multicenter trial of vorinostat in patients with persistent, progressive, or treatment refractory cutaneous T-cell lymphoma.
J Clin Oncol. 2007;25:3109-3115.

Download reprint

 

Duvic M, Talpur R, Ni X, et al. Phase 2 trial of oral vorinostat (suberoylanilide hydroxamic acid, SAHA for refractory cutaneous T-cell lymphoma. Blood. 2007;109:31-39.

Download reprint


Home | Patient Product Information | Prescribing Information
ZOLINZA is a registered trademark of Merck & Co., Inc. Copyright © 2008 Merck & Co., Inc. All rights reserved.

This site is intended only for healthcare professionals of the United States, its territories, and Puerto Rico.

20750170(9)-09/07-ZOL
For general information and other services for physicians
MERCK MEDICUSMERCK SOURCEMERCKServices
MerckMedicus, MerckSource, and MerckServices are trademarks of Merck & Co., Inc.